The psychedelic field is experiencing a shake-up, with trailblazers pushing forward despite a minefield of controversy, red tape, and lingering stigma. Psychiatric medicine has been stuck in a rut, but substances like psilocybin, MDMA, and DMT are the new kids on the block, showing potential to tackle PTSD, depression, anxiety, and addiction like a boss. Investors are hopping on the bandwagon, even though the FDA just gave a thumbs down to MDMA-assisted therapy. Now, advocates are rolling up their sleeves to tackle the scientific, political, regulatory, and ethical hurdles of getting psychedelics a seat at the mainstream medicine table.
Reference: https://www.statnews.com/2024/09/17/psychedelics-drug-development-industry-who-to-know/
Published Date: 2024-09-17